PETX stock news

Aratana (PETX) delivered earnings and revenue surprises of -40.00% and 5.51%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
Aratana (PETX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Last Friday, Elanco announced the acquisition of Aratana Therapeutics and shareholders of Aratana will receive Elanco shares instead. Elanco is adding a good pi Read more

This Biotech Is Going to the Dogs

02:03pm, Saturday, 27'th Apr 2019
Elanco Animal Health said it would acquire Aratana Therapeutics, a biotech that develops dog and cat medicine, in a stock deal valued at about $234 million. Elanco is going to have to learn some new tricks. Read more
Elanco Animal Health Inc (NYSE: ELAN ) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX ). The two companies are partners on the canine drug Galliprant. What Happened The stock-for-stock deal is worth as much as $245 million, Elanco said. A cash contingent value right of 25 cents per share will be granted to Aratana shareholders on the closing date if the drug capromorelin, known by the brand name Entyce, achieves a set sales target prior to the end of 2021, Elanco said. The deal would grant Aratana shareholders 0.1481 Elanco shares and one cash contingent value right for each Aratana share, and … Full story available on Benzinga.com Read more

Earnings movers dominate premarket gainers

01:18pm, Friday, 26'th Apr 2019
Aratana Therapeutics (PETX) +37% on Elanco takeover. Regional Health Properties (RHE) +20%. Reebonz Holding (RBZ) +17%. Highpower (HPJ) +14% on receiving a Read more

Proudly made at

ROCKIT